TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33554371

Group type: EXPERIMENTAL
Intervention: Water Deficit (WD) + Medium Irradiance (MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Well-Watered (WW) + Higher Irradiance (HI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water Deficit (WD) + Higher Irradiance (HI)
Number of subjects: 0
Study: 33330303

Group type: EXPERIMENTAL
Intervention: Exercise Training Group (ETG; n = 35)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Exercise Training Group (ETG; n = 10 with regular adherence)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Reference Group (REF; n = 34)
Number of subjects: 108
Study: 35319484

Group type: EXPERIMENTAL
Intervention: WEB
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: WEB+
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: PRINT
Number of subjects: 242
Study: 32513231

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Nitazoxanide
Number of subjects: 86

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 86
Study: 34000834

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2 grams intravenous)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo (matching intravenous)
Number of subjects: 254
Study: 33151364

Group type: EXPERIMENTAL
Intervention: Mobile Bearing (MB) total knee arthroplasty (TKA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Fixed Bearing (FB) total knee arthroplasty (TKA)
Number of subjects: 160
Study: 32929109

Group type: EXPERIMENTAL
Intervention: Electronic inhaler monitoring devices
Number of subjects: 211
Study: 34961793

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Esaxerenone
Number of subjects: 0
Study: 33234846

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for 4 cycles followed by nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity or a maximum of 48 weeks.
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 754
Study: 32621817

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) for undifferentiated-type EGC
Number of subjects: 175

Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD) for differentiated-type EGC
Number of subjects: 175
Study: 33576394

Group type: EXPERIMENTAL
Intervention: Informational handout detailing U.S. Food and Drug Administration‐recommended ways to properly dispose of leftover opioids (n=188)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Informational handout and a drug disposal kit with instructions on its use (n=170)
Number of subjects: 499

Group type: COMPARATOR
Intervention: No intervention (n=141)
Number of subjects: 499
Study: 32524239

Group type: EXPERIMENTAL
Intervention: Daytime eye rubbing
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Eye rubbing in the morning
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Eye rubbing in eyes with the steepest keratometry
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Allergy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Red eyes in the morning
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sleeping on stomach/sides
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sleeping on the same side as the steepest keratometry
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Daytime eye rubbing (multivariate model)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Eye rubbing in the morning (multivariate model)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Eye rubbing in the steepest eye (multivariate model)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sleeping on stomach/sides (multivariate model)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sleeping on the steepest side (multivariate model)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Eye rubbing (univariate analysis in UHAKC group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sleeping position (univariate analysis in UHAKC group)
Number of subjects: 33
Study: 34119716

Group type: EXPERIMENTAL
Intervention: Self-acupressure via a patient-designed mobile app and hand-held device for 6 weeks
Number of subjects: 165

Group type: COMPARATOR
Intervention: Sham app and device for 6 weeks
Number of subjects: 165

Group type: COMPARATOR
Intervention: No care group
Number of subjects: 165
Study: 33472773

Group type: EXPERIMENTAL
Intervention: Patient Safety Guide for Primary Care (PSG-PC)
Number of subjects: 120
Study: 32441668

Group type: EXPERIMENTAL
Intervention: Fenugreek 400 mg/d
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fenugreek 500 mg/d
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 35138350

Group type: EXPERIMENTAL
Intervention: Optimal secondary prevention
Number of subjects: 1807

Group type: COMPARATOR
Intervention: Missing one or more recommended medications
Number of subjects: 1807
Study: 36388925

Group type: EXPERIMENTAL
Intervention: Ulmus macrocarpa Hance extract (UME) 500 mg (two capsules per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (cornstarch, two capsules per day)
Number of subjects: 80
Study: 32178787

Group type: EXPERIMENTAL
Intervention: Manual Compression (MC)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Closure Pad (CP)
Number of subjects: 238
Study: 35766959

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Thoracic Paravertebral Block (TPVB)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined ESPB and TPVB (comb-group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: TPVB
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ESPB
Number of subjects: 75
Study: 34961418

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 32471494

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low-flow nasal cannula
Number of subjects: 132
Study: 35246497

Group type: EXPERIMENTAL
Intervention: iVAPS
Number of subjects: 30

Group type: COMPARATOR
Intervention: ST
Number of subjects: 30
Study: 36168678

Group type: EXPERIMENTAL
Intervention: Gore-Tex® thyroplasty with prior injection laryngoplasty (IL)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gore-Tex® thyroplasty without prior injection laryngoplasty (IL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gore-Tex® thyroplasty (both groups combined)
Number of subjects: 45
Study: 33719474

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 32862469

Group type: EXPERIMENTAL
Intervention: Intravenous eptinezumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous eptinezumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anchor-based methods for item-level analyses
Number of subjects: 0
Study: 34633168

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study: 33486817

Group type: EXPERIMENTAL
Intervention: Educational handbook in addition to standard AD management
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard management alone
Number of subjects: 175
Study: 35258533

Group type: EXPERIMENTAL
Intervention: Physiologically focused CPR training at the point of care and structured clinical event debriefings; 48 trainings/unit per month and 1 debriefing/unit per month
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Usual pediatric ICU management of cardiac arrest
Number of subjects: 1129
Study: 34763335

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 60
Study: 32593750

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 15
Study: 34839056

Group type: EXPERIMENTAL
Intervention: Non-immersive VR-based serious games (15 sessions, 45 min, 5 times per week)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Non-immersive VR-based serious games
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional balance training (15 sessions, 45 min, 5 times per week)
Number of subjects: 56
Study: 33741668

Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training consisting of three weekly exercise sessions
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Motivational counselling supported by health technology
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 220
Study: 32051195

Group type: EXPERIMENTAL
Intervention: Normal/Fast nicotine metabolizers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow nicotine metabolizers
Number of subjects: 0
Study: 34353294

Group type: EXPERIMENTAL
Intervention: Adherence-focused guidance (AFG)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Self-help (SH)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 404
Study: 32301053

Group type: EXPERIMENTAL
Intervention: Intradialytic combined exercise (24-week, three times weekly, moderate-intensity)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 47
Study: 35196310

Group type: EXPERIMENTAL
Intervention: Virtually Augmented Self-Hypnosis (VA-HYPO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no VA-HYPO)
Number of subjects: 100
Study: 32773365

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Breathing Exercises (BG)
Number of subjects: 54
Study: 34452729

Group type: EXPERIMENTAL
Intervention: LiFT program participants
Number of subjects: 786

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 786
Study: 32506309

Group type: EXPERIMENTAL
Intervention: FDC of IBU/APAP 200 mg/500 mg
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: FDC of IBU/APAP 250 mg/500 mg
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: FDC of IBU/APAP 300 mg/500 mg
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study: 35166009

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10/25 mg/day)
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study: 33130153

Group type: EXPERIMENTAL
Intervention: Tailored cognitive behavioral therapy (ADAPT) plus medical treatment as usual
Number of subjects: 139

Group type: COMPARATOR
Intervention: Medical treatment as usual only
Number of subjects: 139
Study: 35909479

Group type: EXPERIMENTAL
Intervention: Posterior auricular injection (retroauricular group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tympanum injection (tympanic group)
Number of subjects: 46
Study: 33988940

Group type: EXPERIMENTAL
Intervention: Short-term spinal cord stimulation (stSCS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 96
Study: 32777605

Group type: EXPERIMENTAL
Intervention: Nurse-led proactive self-care program
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 457
Study: 36519447

Group type: EXPERIMENTAL
Intervention: vancomycin‐preceded FMT, N = 24
Number of subjects: 64

Group type: COMPARATOR
Intervention: vancomycin, N = 16
Number of subjects: 64

Group type: COMPARATOR
Intervention: fidaxomicin, N = 24
Number of subjects: 64
Study: 34126641

Group type: EXPERIMENTAL
Intervention: Anterior Thalamic Stimulation (ANT DBS)
Number of subjects: 0
Study: 32314939

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA) with continuous postoperative epidural analgesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: General anesthesia (GA) with patient‐controlled intravenous analgesia
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both SA and GA
Number of subjects: 44
Study: 36141488

Group type: EXPERIMENTAL
Intervention: High-impact training (G1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-impact training + calcium and vitamin D intake (G2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Walking at an intense pace + calcium and vitamin D (G3)
Number of subjects: 39
Study: 32949463

Group type: EXPERIMENTAL
Intervention: Seropositivity to Echinococcus granulosus
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Locality
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Contact with dogs
Number of subjects: 305
Study: 35761343

Group type: EXPERIMENTAL
Intervention: Multicomponent nurse-led family support intervention
Number of subjects: 896

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 896
Study: 33539749

Group type: EXPERIMENTAL
Intervention: Short‐course radiotherapy followed by chemotherapy before total mesorectal excision (TME)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy
Number of subjects: 0
Study: 32723668

Group type: EXPERIMENTAL
Intervention: Corrective exercise program for 8 weeks, 30 min/d, 3 days per week
Number of subjects: 32
Study: 35286849

Group type: EXPERIMENTAL
Intervention: MDMA‐AT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo+Therapy
Number of subjects: 90
Study: 34595804

Group type: EXPERIMENTAL
Intervention: IV fluids
Number of subjects: 470

Group type: COMPARATOR
Intervention: No IV fluids
Number of subjects: 470
Study: 35537094

Group type: EXPERIMENTAL
Intervention: Home‐based and mobile HIV‐testing campaigns in intervention communities
Number of subjects: 18597
Study: 32179448

Group type: EXPERIMENTAL
Intervention: Bevacizumab arm (n=23)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard arm (n=26)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for all patients
Number of subjects: 49
Study: 36052360

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 10 mg kg−1
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 95
Study: 35862389

Group type: EXPERIMENTAL
Intervention: 200% recommended dose of fertilizer (RDF) with planting in the first week of October
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200% recommended dose of fertilizer (RDF) with planting in the second week of October
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150% recommended dose of fertilizer (RDF) with planting in the first week of October
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100% recommended dose of fertilizer (RDF) with planting in the first week of October
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150% recommended dose of fertilizer (RDF) with planting in the first fortnight of October
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150% recommended dose of fertilizer (RDF) with planting in the second week of October
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100% recommended dose of fertilizer (RDF) with planting in the first and second week of October
Number of subjects: 0
Study: 33666554

Group type: EXPERIMENTAL
Intervention: HealthyMoms app
Number of subjects: 19
Study: 33189900

Group type: EXPERIMENTAL
Intervention: GSK2798745
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 35972131

Group type: EXPERIMENTAL
Intervention: Medically tailored meals (MTMs)
Number of subjects: 1977
Study: 33479440

Group type: EXPERIMENTAL
Intervention: Primed participants (immersed in a real environment with olfactory and visual cues)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Primed participants
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Primed participants with insight
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non primed participants
Number of subjects: 49
Study: 32197373

Group type: EXPERIMENTAL
Intervention: High sugar sweetened beverage (hiSSB) dietary pattern
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low sugar sweetened beverage (loSSB) dietary pattern
Number of subjects: 101
Study: 34989804

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg/0.05 mL)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg/0.05 mL)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 mL)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Persistent ME
Number of subjects: 425
Study: 34362029

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 90
Study: 36090766

Group type: EXPERIMENTAL
Intervention: Auriculotemporal nerve block (ANB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gow-Gates (GG) mandibular anesthesia
Number of subjects: 40
Study: 35876254

Group type: EXPERIMENTAL
Intervention: Discharge planning
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Treatments
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Warning signs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 66
Study: 33803694

Group type: EXPERIMENTAL
Intervention: 8-week CrossFit training program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 34644619

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Moderate/high-intensity exercise training
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (standard treatment/non-exercise)
Number of subjects: 286
Study: 34767839

Group type: EXPERIMENTAL
Intervention: Stimulus-focused reappraisal
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Goal-based reappraisal
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control instruction
Number of subjects: 86
Study: 35240678

Group type: EXPERIMENTAL
Intervention: Attended AOBP
Number of subjects: 133

Group type: COMPARATOR
Intervention: Unattended AOBP
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 5 minutes of rest
Number of subjects: 133

Group type: COMPARATOR
Intervention: 15 minutes of rest
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: AOBP after 5 minutes of rest
Number of subjects: 133

Group type: COMPARATOR
Intervention: Daytime ABPM
Number of subjects: 133
Study: 34674750

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (4200 mg)
Number of subjects: 1300000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300000
Study: 32342841

Group type: EXPERIMENTAL
Intervention: Azithromycin MDA
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 36187057

Group type: EXPERIMENTAL
Intervention: Smartphone WeChat application (group A)
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Conventional education plus smartphone WeChat application (group B)
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 1428
Study: 33357601

Group type: EXPERIMENTAL
Intervention: Values clarification exercise
Number of subjects: 93

Group type: COMPARATOR
Intervention: Time management control condition
Number of subjects: 93
Study: 33506798

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injection
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 45
Study: 32588653

Group type: EXPERIMENTAL
Intervention: 20-minute mindful breathing plus standard care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 30
Study: 33573486

Group type: EXPERIMENTAL
Intervention: NPWT+ (Negative Pressure Wound Therapy Plus)
Number of subjects: 59

Group type: COMPARATOR
Intervention: NPWT (Negative Pressure Wound Therapy)
Number of subjects: 59
Study: 33058694

Group type: EXPERIMENTAL
Intervention: CRTT‐R‐WF‐Cantonese
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CRTT‐L‐Cantonese
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cantonese Aphasia Battery
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CRTT‐Cantonese tests
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CRTT‐R‐WF‐Cantonese and CRTT‐L‐Cantonese
Number of subjects: 74
Study: 35831149

Group type: EXPERIMENTAL
Intervention: Buddy Balloon Technique (BBT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Buddy Wire Technique (BWT)
Number of subjects: 66
Study: 33972624

Group type: EXPERIMENTAL
Intervention: Polymorphic SSR markers (51 selected from 111 polymorphic primer pairs)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Genetic structure analysis of C. japonica
Number of subjects: 89
Study: 32529811

Group type: EXPERIMENTAL
Intervention: CCTA at 120 kVp
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CCTA at 100 kVp
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CCTA at 80 kVp
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CCTA at 70 kVp
Number of subjects: 240
Study: 35315950

Group type: EXPERIMENTAL
Intervention: Same-race/ethnicity expert endorsements
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Different-race/ethnicity expert endorsements
Number of subjects: 2117

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2117
Study: 35996467

Group type: EXPERIMENTAL
Intervention: Double-way SMS intervention
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Single-way SMS intervention
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Combined single-way and double-way SMS
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 294
Study: 33206786

Group type: EXPERIMENTAL
Intervention: Whole purple grape juice (400 ml; 200 ml before and 200 ml after training)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (water; 400 ml; 200 ml before and 200 ml after training)
Number of subjects: 15
Study: 32520900

Group type: EXPERIMENTAL
Intervention: Transdermal 17β estradiol (tE2) 50μg/d
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (oCEE) 0.45mg/d
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78